Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.

MLA

Reich, Kristian, et al. “Risankizumab Compared with Adalimumab in Patients with Moderate-to-Severe Plaque Psoriasis (IMMvent): A Randomised, Double-Blind, Active-Comparator-Controlled Phase 3 Trial.” Lancet (London, England), vol. 394, no. 10198, Aug. 2019, pp. 576–86. EBSCOhost, https://doi.org/10.1016/S0140-6736(19)30952-3.

APA

Reich, K., Gooderham, M., Thaçi, D., Crowley, J. J., Ryan, C., Krueger, J. G., Tsai, T.-F., Flack, M., Gu, Y., Williams, D. A., Thompson, E. H. Z., & Paul, C. (2019). Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet (London, England), 394(10198), 576–586. https://doi.org/10.1016/S0140-6736(19)30952-3

Chicago

Reich, Kristian, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, et al. 2019. “Risankizumab Compared with Adalimumab in Patients with Moderate-to-Severe Plaque Psoriasis (IMMvent): A Randomised, Double-Blind, Active-Comparator-Controlled Phase 3 Trial.” Lancet (London, England) 394 (10198): 576–86. doi:10.1016/S0140-6736(19)30952-3.